sellside ER and the "sell" recommendation

i was wondering: i understand that a role of the sellside equity analyst is also "marketing" the company he/she covers and therefore can't place many "sell" recommendations unless he/she wants to lose access to the management but, given that the major part of the money inflow comes from the buyside, shouldn't the analyst be a little bit more "brave" when it comes down to choose the recommendation?

i am well aware that many buyside professionals use the sellside analysts not for the quality of their financial models inputs but rather for the accuracy of information they acquire but still, isn't the buy/hold/sell present to mean something?

 
Best Response

Sell-side analysts usually cover 1 sub-sector, and generally evaluate those companies on a relative basis. So they might not pick-up on the over/under-valuation of their vertical.

And analysts almost never make broader calls about the market - just about everything should have been rated "buy" in mid-2009.

There are aren't that many straightforward "sells". You might think "this stock is a awful unless XYZ event occurs." Well, there is probably a fund manager somewhere who is betting on that event occurring. So, for that guy, it is a "buy". As an analyst, you have a broad audience, so that stock might be a hold.

Buy/Sell/Hold ratings are really a gross oversimplification. It is almost impossible to put a company neatly into one of 3 buckets. You need to read the note, and ideally talk to the analyst. And if you're going to do all that, I'd say you should do your own work.

I would defer to analysts on a few niches (energy, financials, biotech/pharma, NatRes). But then you are also relying on the analyst to get you out of the stock... it's not a great situation to be in.

 

Tech is honestly much easier. You don't need to understand exactly how a router works to understand CSCO. If you can understand their competitive positions, that's good enough. Most also trade on earnings (and the ones that don't tend to trade on perception).

The industries I mentioned require expertise. Biotech investing depends on you being able to understand the results of clinical trials and the FDA approval process, not to mention the end market for the product.

Financials and Energy/NatRes have their own issues. Models, metrics, and accounting are completely different. As a financials analyst, I can jump into a consumer goods niche and ramp up in a week or so. The reverse cannot happen. Some O&G niches (e.g. drilling rigs) are almost impossible to model effectively without some sector expertise.

I'd also say utilities analysts deserve some credit. The modeling isn't bad, but they need to understand regulation and the dynamics of public-private partnerships.

 

Dolor qui quia dolore id non est. Sequi praesentium facilis delectus consequuntur. Et blanditiis unde ex fugiat laudantium ut adipisci. Cum consequatur nesciunt harum. Voluptatem deleniti quo maiores ab reprehenderit ad nihil aliquid. Dolores explicabo cupiditate reiciendis doloremque deleniti voluptatem cupiditate. Modi ut amet provident non ex ut dolorem.

Cumque ad nesciunt quo neque. Praesentium sed odit accusamus eum amet. Eos quia unde molestiae ducimus. Illo consectetur reiciendis sit inventore. Odit nulla provident atque.

Neque pariatur est et assumenda magnam. Laboriosam deserunt non rerum temporibus laudantium ut voluptate. Sed illo qui sint voluptas. In culpa laborum dolor modi minus. Impedit qui eum aut non nisi aut.

Career Advancement Opportunities

March 2024 Investment Banking

  • Jefferies & Company 02 99.4%
  • Goldman Sachs 19 98.8%
  • Harris Williams & Co. (++) 98.3%
  • Lazard Freres 02 97.7%
  • JPMorgan Chase 03 97.1%

Overall Employee Satisfaction

March 2024 Investment Banking

  • Harris Williams & Co. 18 99.4%
  • JPMorgan Chase 10 98.8%
  • Lazard Freres 05 98.3%
  • Morgan Stanley 07 97.7%
  • William Blair 03 97.1%

Professional Growth Opportunities

March 2024 Investment Banking

  • Lazard Freres 01 99.4%
  • Jefferies & Company 02 98.8%
  • Goldman Sachs 17 98.3%
  • Moelis & Company 07 97.7%
  • JPMorgan Chase 05 97.1%

Total Avg Compensation

March 2024 Investment Banking

  • Director/MD (5) $648
  • Vice President (19) $385
  • Associates (86) $261
  • 3rd+ Year Analyst (13) $181
  • Intern/Summer Associate (33) $170
  • 2nd Year Analyst (66) $168
  • 1st Year Analyst (202) $159
  • Intern/Summer Analyst (144) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
Secyh62's picture
Secyh62
99.0
3
Betsy Massar's picture
Betsy Massar
99.0
4
BankonBanking's picture
BankonBanking
99.0
5
kanon's picture
kanon
98.9
6
CompBanker's picture
CompBanker
98.9
7
GameTheory's picture
GameTheory
98.9
8
dosk17's picture
dosk17
98.9
9
DrApeman's picture
DrApeman
98.9
10
bolo up's picture
bolo up
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”